For example, T2D is associated with smaller brain volumes, accelerated rates of brain atrophy, reduced cerebral blood flow in predilection sites for AD pathology (e.g., medial temporal lobe, inferior parietal regions), reductions in cerebral glucose metabolic rate (CMRglu) (7–15, 19), and higher cerebrospinal fluid (CSF) levels of the AD pathological marker hyperphosphorylated tau (p-tau) (16–18). This evidence concerns the gene MAPT and Alzheimer disease.